TIDMN4P

N4 Pharma PLC

27 June 2023

Reach - Non-Regulatory

27 June 2023

N4 Pharma Plc

("N4 Pharma" or the "Company")

Grant Award for Professor Chengzhong Yu

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec(R), a novel delivery system for cancer treatments and vaccines, is pleased to announce it will be supporting the University of Queensland as part of a recent grant award by the Australian Research Council.

The University of Queensland has announced that Professor Chengzhong Yu, Senior Group Leader, Australian Institute for Bioengineering and Nanotechnology (AIBN) has been awarded a $402,115 grant to develop an improved nanoparticle delivery system that enhances the performance of messenger ribonucleic acid (mRNA) therapies. The new nanoparticle will be based on the Company's patented nuvec(R) nanoparticle that it has licensed exclusively from the University of Queensland.

N4 Pharma will work with Professor Yu to tackle the current challenges in manufacturing mRNA therapeutics, by building new knowledge in custom-design of functional nanomaterials for mRNA delivery. mRNA is a highly lucrative field of therapeutic science and is emerging as a major drug platform.

A copy of the full announcement can be found here: https://aibn.uq.edu.au/article/2023/06/linkage-grants-catapult-lab-ideas-production-line

Nigel Theobald, Chief Executive Officer of the Company, commented:

"We are pleased to continue our close collaboration with Professor Yu and work on new ways to build on the performance of our Nuvec(R) nanoparticle together."

Enquiries:

 
 N4 Pharma Plc                                  Via IFC Advisory 
  Nigel Theobald, CEO 
  Luke Cairns, Executive Director 
 
 SP Angel Corporate Finance LLP                 Tel: + 44 (0)20 3470 
  Nominated Adviser and Joint Broker             0470 
  Matthew Johnson/Kasia Brzozowska (Corporate 
  Finance) 
  Vadim Alexandre/Rob Rees (Corporate 
  Broking) 
 
 Turner Pope Investments (TPI) Limited          Tel: +44 (0)20 3657 
  Joint Broker                                   0050 
  Andy Thacker 
 
  IFC Advisory Limited 
  Financial PR                                   Tel: +44 (0)20 3934 
  Graham Herring                                 6630 
  Zach Cohen

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec(R).

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec(R) as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre-clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRANKABPNBKDBAB

(END) Dow Jones Newswires

June 27, 2023 02:00 ET (06:00 GMT)

N4 Pharma (LSE:N4P)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024 Click aqui para mais gráficos N4 Pharma.
N4 Pharma (LSE:N4P)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024 Click aqui para mais gráficos N4 Pharma.